Background: Bortezomib with dexamethasone is a standard treatment option for relapsed or refractory multiple myeloma. Carfilzomib with dexamethasone has shown promising activity in patients in this disease setting. The aim of this study was to compare the combination of carfilzomib and dexamethasone with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Methods: In this randomised, phase 3, open-label, multicentre study, patients with relapsed or refractory multiple myeloma who had one to three previous treatments were randomly assigned (1: 1) using a blocked randomisation scheme (block size of four) to receive carfilzomib with dexamethasone (carfilzomib group) or bortezomib with dexamethasone (bortezomib group). Randomisation was stratified by previous proteasome inhibitor therapy, previous lines of treatment, International Staging System stage, and planned route of bortezomib administration if randomly assigned to bortezomib with dexamethasone. Patients received treatment until progression with carfilzomib (20 mg/m(2) on days 1 and 2 of cycle 1; 56 mg/m(2) thereafter; 30 min intravenous infusion) and dexamethasone (20 mg oral or intravenous infusion) or bortezomib (1 × 3 mg/m(2); intravenous bolus or sub-
belegt. In der Subgruppe der Patienten mit 2 Vortherapien inklusive Immunmodulator und Bortezomib, für die nun die Zulassung vorliegt, betrug der PFS-Vorteil sogar 12 vs. 5 Monate [5] . Interessanterweise konnte die Phase-II-Studie PANORAMA-2 [6] für FVD eine Ansprechrate von gut einem Drittel bei Patienten mit BortezomibRefraktärität nachweisen. An Nebenwirkungen sind unter Panobinostat speziell Fatigue, welche vor allem bei älteren Patienten ausgeprägt sein kann, Thrombozytopenie und Diarrhoe zu beachten. Elotuzumab als monoklonaler Anti-SLAMF7-Antikörper war in der Phase-III-Studie ELOQUENT-2 [7] in Kombination mit Lenalidomid und Dexamethason (Elo-RD) der Standardtherapie mit letzteren beiden Substanzen überlegen; der PFS Vorteil betrug 19 vs. 15 Monate. Zudem war das Intervall bis zum Beginn der nächsten Therapie nach Elo-RD um 12 Monate länger als nach RD. Diese gut verträgliche Therapie ist für Patienten mit mindestens einer Vortherapie zugelassen. Daratumumab richtet sich gegen das Oberflächenmolekül CD38 und ist als Monotherapie auch bei stark vorbehandelten Patienten wirksam. In der Phase-II-Studie SIRIUS [8] und in einer weiteren Phase-I/II Studie [9] Background: Bortezomib with dexamethasone is a standard treatment option for relapsed or refractory multiple myeloma. Carfilzomib with dexamethasone has shown promising activity in patients in this disease setting. The aim of this study was to compare the combination of carfilzomib and dexamethasone with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Methods: In this randomised, phase 3, open-label, multicentre study, patients with relapsed or refractory multiple myeloma who had one to three previous treatments were randomly assigned (1: 1) using a blocked randomisation scheme (block size of four) to receive carfilzomib with dexamethasone (carfilzomib group) or bortezomib with dexamethasone (bortezomib group). Randomisation was stratified by previous proteasome inhibitor therapy, previous lines of treatment, International Staging System stage, and planned route of bortezomib administration if randomly assigned to bortezomib with dexamethasone. Patients received treatment until progression with carfilzomib (20 mg/m(2) on days 1 and 2 of cycle 1; 56 mg/m(2) thereafter; 30 min intravenous infusion) and dexamethasone (20 mg oral or intravenous infusion) or bortezomib (1 × 3 mg/m(2); intravenous bolus or sub-Karger Kompass Onkol 2016;3:92-95 cutaneous injection) and dexamethasone (20 mg oral or intravenous infusion). The primary endpoint was progression-free survival in the intention-to-treat population. All participants who received at least one dose of study drug were included in the safety analyses. The study is ongoing but not enrolling participants; results for the interim analysis of the primary endpoint are presented. The trial is registered at ClinicalTrials.gov, number NCT01568866. Findings: Between June 20, 2012, and June 30, 2014, 929 patients were randomly assigned (464 to the carfilzomib group; 465 to the bortezomib group). Median follow-up was 11 × 9 months (IQR 9 × 3-16 × 1) in the carfilzomib group and 11 × 1 months (8 × 2-14 × 3) in the bortezomib group. Median progression-free survival was 18 × 7 months (95% CI 15 × 6 -not estimable) in the carfilzomib group versus 9 × 4 months (8 × 4-10 × 4) in the bortezomib group at a preplanned interim analysis (hazard ratio [ Background: Panobinostat is a potent oral pan-deacetylase inhibitor that in preclinical studies has synergistic anti-myeloma activity when combined with bortezomib and dexamethasone. We aimed to compare panobinostat, bortezomib, and dexamethasone with placebo, bortezomib, and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma. Methods: PANORAMA1 is a multicentre, randomised, placebo-controlled, double-blind phase 3 trial of patients with relapsed or relapsed and refractory multiple myeloma who have received between one and three previous treatment regimens. Patients were randomly assigned (1: 1) via an interactive web-based and voice response system, stratified by number of previous treatment lines and by previous use of bortezomib, to receive 21 day cycles of placebo or panobinostat (20 mg; on days 1, 3, 5, 8, 10, 12, orally), both in combination with bortezomib (1 × 3 mg/m(2) on days 1, 4, 8, 11, intravenously) and dexamethasone (20 mg on days 1, 2, 4, 5, 8, 9, 11, 12, orally). Patients, physicians, and the investigators who did the data analysis were masked to treatment allocation; crossover was not permitted. The primary endpoint was progression-free survival (in accordance with modified European Group for Blood and Marrow Transplantation criteria and based on investigators' assessment) and was analysed by intention to treat. The study is ongoing, but no longer recruiting, and is registered at ClinicalTrials.gov, number NCT01023308. Findings: 768 patients were enrolled between Jan 21, 2010, and Feb 29, 2012, with 387 randomly assigned to panobinostat, bortezomib, and dexamethasone and 381 to placebo, bortezomib, and dexamethasone. Median followup was 6 × 47 months (IQR 1 × 81-13 × 47) in the panobinostat group and 5 × 59 months (2 × 14-11 × 30) in the placebo group. Median progressionfree survival was significantly longer in the panobinostat group than in the placebo group (11 × Minimal responses were noted in 23 (6%) patients in the panobinostat group and in 42 (11%) in the placebo group. Median duration of response (partial response or better) was 13 × 14 months (95% CI 11 × 76-14 × 92) in the panobinostat group and 10 × 87 months (9 × 23-11 × 76) in the placebo group, and median time to response (partial response or better) was 1 × 51 months (1 × 41-1·64) in the panobinostat group and 2 × 00 months (1 × 61-2 × 79) in the placebo group. Serious adverse events were reported in 228 (60%) of 381 patients in the panobinostat group and 157 (42%) of 377 patients in the placebo group. Background: Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. Methods: In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (elotuzumab group) or lenalidomide and dexamethasone alone (control group). Coprimary end points were progression-free survival and the overall response rate. Final results for the coprimary end points are reported on the basis of a planned interim analysis of progression-free survival. Results: Overall, 321 patients were assigned to the elotuzumab group and 325 to the control group. After a median follow-up of 24.5 months, the rate of progression-free survival at 1 year in the elotuzumab group was 68%, as compared with 57% in the control group; at 2 years, the rates were 41% and 27%, respectively. Median progression-free survival in the elotuzumab group was 19.4 months, versus 14.9 months in the control group (hazard ratio for progression or death in the elotuzumab group, 0.70; 95% confidence interval, 0.57 to 0.85; P < 0.001). The overall response rate in the elotuzumab group was 79%, versus 66% in the control group (P < 0.001). Common grade 3 or 4 adverse events in the two groups were lymphocytopenia, neutropenia, fatigue, and pneumonia. Infusion reactions occurred in 33 patients (10%) in the elotuzumab group and were grade 1 or 2 in 29 patients. Conclusions: Patients with relapsed or refractory multiple myeloma who received a combination of elotuzumab, lenalidomide, and dexamethasone had a significant relative reduction of 30% in the risk of disease progression or death. (Funded by Bristol-Myers Squibb and AbbVie Biotherapeutics; ELO-QUENT-2 ClinicalTrials.gov number, NCT01239797.).
